Investing.com - Repligen (NASDAQ: RGEN) reported fourth quarter EPS of $0.33, in line with the analyst estimate of $0.33. Revenue for the quarter came in at $155.7M versus the consensus estimate of $155.38M.
Guidance
Repligen sees Q1 2024 EPS of $1.42-$1.49 versus the analyst consensus of $1.77.
Repligen sees Q1 2024 revenue of $620.00M-$650.00M versus the analyst consensus of $660.70M.
Repligen's stock price closed at $199.73. It is up 23.46% in the last 3 months and up 17.50% in the last 12 months.
Repligen saw 0 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Repligen's stock price’s past reactions to earnings here.
According to InvestingPro, Repligen's Financial Health score is "great performance".
Check out Repligen's recent earnings performance, and Repligen's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar